Alkermes (ALKS)
(Delayed Data from NSDQ)
$26.43 USD
-0.94 (-3.43%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $26.42 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth C Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALKS 26.43 -0.94(-3.43%)
Will ALKS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ALKS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALKS
Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term
Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term
ALKS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Alkermes (ALKS) is a Strong Value Stock
Here's Why Alkermes (ALKS) is a Strong Value Stock
Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report?
Other News for ALKS
Alkermes to Host Investor Event to Review Orexin Portfolio Strategy
Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024
Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference
IHF: Healthcare Dashboard For September
Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)